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Serine/arginine (SR) proteins, one of the major families of alternative-
splicing regulators in Eukarya, have two types of RNA-recognition
motifs (RRMs): a canonical RRM and a pseudo-RRM. Although
pseudo-RRMs are crucial for activity of SR proteins, their mode of
action was unknown. By solving the structure of the human SRSF1
pseudo-RRM bound to RNA, we discovered a very unusual and
sequence-speciﬁc RNA-binding mode that is centered on one α-helix
and does not involve the β-sheet surface, which typically mediates
RNA binding by RRMs. Remarkably, this mode of binding is conserved
in all pseudo-RRMs tested. Furthermore, the isolated pseudo-
RRM is sufﬁcient to regulate splicing of about half of the SRSF1
target genes tested, and the bound α-helix is a pivotal element
for this function. Our results strongly suggest that SR proteins
with a pseudo-RRM frequently regulate splicing by competing
with, rather than recruiting, spliceosome components, using solely
this unusual RRM.
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Serine/arginine (SR) proteins are highly conserved in Eukaryaand are key regulators of gene expression. These proteins are
required for pre-mRNA splicing, regulate alternative splicing
events, and play crucial roles in genomic stability, mRNA tran-
scription, nuclear export, nonsense-mediated mRNA decay, and
translation (1–5). Several studies have revealed links between
these proteins and diseases (6), making the proteins potential
therapeutic targets (7). For the last two decades, SR proteins
have been studied intensively as regulators of alternative splicing,
a mechanism used to modulate the expression of more than 95%
of human genes (8, 9). Importantly, it is estimated that 15–50%
of human disease-causing mutations affect splicing (10). Alter-
native splicing consists of the alternative selection of splice sites
present within pre-mRNA, leading to different versions of ma-
ture mRNAs from a single gene (11). As a result, in some cases,
proteins with opposite functions can be generated. In the context
of cancer, alternative splicing can generate pro- or antiapoptotic
isoforms (12). As an example, alternatively spliced variants of
FAS/CD95 can be generated by inclusion or skipping of exon 6,
depending on competition between antagonistic splicing factors
(13–16). In the absence of Fas exon 6, the apoptotic receptor
lacks the transmembrane domain and becomes soluble and
antiapoptotic (17).
Each SR protein has a modular structure with one or two
RNA-recognition motifs (RRMs) at its N-terminal part, followed
by a C-terminal arginine-serine–rich (RS) domain containing
multiple RS dipeptide repeats. In many cases, SR proteins have
been shown to interact with purine-rich exonic splicing enhanc-
ers (ESEs) and to promote inclusion of the targeted exon in
mRNAs (18). Two main models have been proposed to explain
the mode of action of ESE-bound SR proteins in splicing regu-
lation. In the recruitment model SR proteins recruit U1-70K
and/or U2AF35 to 5′ and 3′ splice sites, respectively, to promote
spliceosome assembly (4). In the inhibitor model SR proteins
activate splicing by preventing the binding of splicing repressors,
such as hnRNP A1, around the regulated splice site (4). In some
cases, SR proteins have been shown not to enhance splicing but
rather to promote exon skipping (19–26). However, their mode
of action in these cases is still unclear.
The RS domain of SR proteins was shown to be important for
splicing, because it initiates spliceosome recruitment by inter-
acting with the branchpoint sequence (27) and/or spliceosomal
components (28–30). However, in some cases, this domain also
can be dispensable for constitutive and enhancer-dependent
splicing (31), indicating a key function of the RRMs in this
process. Although previously it was shown that the RRMs of
SRSF1 can contact the spliceosomal component U1-70K directly
(32), the main role of the RRMs seems to be to provide RNA-
binding speciﬁcity and to dictate the position of SR proteins on
pre-mRNAs (18).
The oncoprotein SRSF1 (SF2/ASF) (33–36) is one of the best-
studied SR proteins. Depletion of SRSF1 protein results in death
in chicken cells (37) and embryonic lethality in Caenorhabditis
elegans (38). Like all SR proteins containing two RRMs, it
comprises an N-terminal canonical RRM followed by a pseudo-
RRM (Fig. 1A). Although pseudo-RRMs appear to be critical
for the activity of SR proteins (39–42), their mode of action still
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tein family contain a noncanonical RNA recognition motif
(RRM), the pseudo-RRM, for which the mode of RNA recogni-
tion is unknown. Here, we solved the structure of SRSF1
pseudo-RRM bound to RNA. It reveals the RNA motif recog-
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served for all the SR proteins containing pseudo-RRMs. Finally,
we show that the pseudo-RRM in isolation often is sufﬁcient to
regulate splicing, and we reveal its mechanism of action.
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needs to be clariﬁed. Unlike canonical RRMs, pseudo-RRMs
have a conserved, distinctive, invariant heptapeptide, SWQDLKD,
on their α-helix 1 (43). In addition, their β-sheet surface lacks
the set of conserved aromatic residues usually involved in RNA
binding (44), suggesting that this domain uses an unusual mode
of RNA recognition.
In this study, we solved the NMR structure of SRSF1 pseudo-
RRM bound to RNA. The structure reveals that the domain
speciﬁcally binds a GGA motif, primarily using the conserved
residues located in α-helix 1. Remarkably, this unusual mode of
RNA recognition is conserved for all pseudo-RRMs we tested
from human, yeast, and ﬂy. Moreover, we show that the isolated
pseudo-RRM can regulate many different alternative splicing
events as effectively as the full-length protein. Finally, our data
suggest that the pseudo-RRM acts in splicing regulation by
competing with binding of other splicing factors rather than by
recruiting them to the cassette exon.
Results
SRSF1 Interacts with Purine-Rich Sequences Using only Its Pseudo-RRM.
SRSF1 (SF2/ASF) (34, 35) consists of two RRMs responsible
for RNA recognition and one C-terminal RS domain (Fig. 1A)
(18). The RNA-binding speciﬁcity of SRSF1 is still unclear.
The consensus sequence 5′-ACGCGCA-3′ was determined by
SELEX in the presence of the N-terminal canonical RRM alone
(RRM1), whereas guanine-adenine (GA)–rich RNA sequen-
ces were selected with a version of SRSF1 with both RRMs
(45). Because purine-rich sequences are found in natural ESEs
bound by SRSF1 (46), we investigated the contribution of each
RRM in binding to this type of sequence. We used a 5′-AGGA-
GAAC-3′ RNA, which was selected by SELEX and had the highest
afﬁnity for the SRSF1 protein containing the two RRMs (45).
Overlay of 1H-15N heteronuclear single-quantum coherence
(HSQC) spectra recorded with the RNA-bound form of each
isolated RRM and a protein with both RRMs connected by their
A B
C D
Fig. 1. SRSF1 pseudo-RRM interaction with 5′-UGAAGGAC-3′ RNA. (A) The sequence of recombinant SRSF1 protein used in this study is shown. Amino acid
numbering is according to the PDB sequence. Amino acids involved in the formation of β-strands and α-helices are underlined. (B) Superimposition of 1H-15N
HSQC spectra representing NMR titration of the 15N-labeled SRSF1 pseudo-RRM with increasing amounts of unlabeled 5′-UGAAGGAC-3′ RNA. The titration
was performed at 40 °C in NMR buffer. The peaks corresponding to the free and RNA-bound protein states (RNA:protein ratios of 0.3:1 and 1:1) are colored
blue, orange, and red, respectively. The negative peaks, corresponding to the amides of arginine side-chains in the free and RNA-bound (1:1 ratio) states are
colored green and magenta, respectively. The highest chemical-shift perturbations observed upon RNA binding are indicated by black arrows. (C) Kd de-
termination of SRSF1 pseudo-RRM in complex with 5′-UGAAGGAC-3′ RNA by ITC. The measured Kd value is indicated. (D) Representation of the combined
chemical-shift perturbations (Δδ = [(δHN)2 + (δN/6.51)2]1/2) of SRSF1 pseudo-RRM amides upon 5′-UGAAGGAC-3′ RNA binding, as a function of the pseudo-
RRM amino acid sequence. Secondary-structure elements of the protein domain are displayed at the bottom of the graph. The highest chemical-shift per-
turbations are indicated.
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natural linker showed that chemical shifts are similar (SI Ap-
pendix, Fig. S1A). This analysis reveals that, upon RNA binding,
the RRMs behave similarly when they are separated or linked in
their natural conformation. In addition, isothermal titration
calorimetry (ITC) measurements indicated that only the pseudo-
RRM interacts efﬁciently with the purine-rich sequence tested
(SI Appendix, Fig. S1B), demonstrating that SRSF1 RRM2 is the
primary domain for recognition of purine-rich ESEs. There-
fore, we investigated the RNA-binding mode of this domain
using NMR spectroscopy. To obtain NMR spectra of sufﬁcient
quality for structure determination, we tested several RNA se-
quences derived from SELEX (45) and CLIP consensus (46).
High-quality NMR spectra were obtained with SRSF1 RRM2
(amino acids 107–203) fused to the solubility tag GB1 and bound
to 5′-UGAAGGAC-3′ (Fig. 1B). Importantly, this sequence
ﬁts the consensus sequence determined by CLIP with SRSF1
(5′-UGA/GU/AGA/GA/U-3′) (46). We measured a dissociation con-
stant of 0.8 μM for this complex, using ITC (Fig. 1C). NMR
titration revealed large chemical shift perturbations in the β2-strand
and, more surprisingly in the α-helix 1 and N-terminal extremity
of the domain (Fig. 1D). We calculated the structure of this
complex using 1,487 nuclear Overhauser effect (NOE)-derived
distance restraints, including 38 intermolecular ones (SI Appendix,
Table S1 and Fig. S2). We obtained a very precise ensemble of
16 structures (Fig. 2A) with an rmsd of 0.92 Å for all of the heavy
atoms (SI Appendix, Table S1).
SRSF1 Pseudo-RRM Uses α-Helix 1 to Recognize GGA. The pseudo-
RRM in complex with RNA adopted a canonical β1α1β2β3α2β4
fold that is unchanged compared with the non–ligand-bound
(apo) form of the protein (47). The RNA structure adopted an
extended conformation with all nucleotides in the C2′-endo sugar
conformation, except for G5, which had a C3′-endo conformation
(Fig. 2). The mode of binding is very unusual for an RRM, be-
cause the RNA-binding site is centered on α-helix 1, and the
β-sheet surface does not contact the RNA (Fig. 2 B and C). The
pseudo-RRM recognizes only three of the eight nucleotides, G5,
G6, and A7, which wrap the bottom of α-helix 1. The N-terminal
part of this helix, comprising Ser133, Trp134, and Gln135, forms
an ideal surface for binding three nucleotides, with G5 stacking
on the Trp134 side-chain, G6 stacking on the main-chain, and A7
stacking over the surface formed by the Ser133 and Gln135 side-
chains (Fig. 2 C and D). Additionally, the side-chains of Trp134
and Gln135 interact with the sugar rings of G5 and G6, re-
spectively. All these contacts provide afﬁnity for the three
nucleotides and organize the GGA triplet into an arch with two
consecutive bases perpendicular to one another, but they do not
confer sequence speciﬁcity. Sequence speciﬁcity is achieved by
other features of the pseudo-RRM. The Watson–Crick edges of
G5 and G6 are recognized by several hydrogen bonds formed
with the main-chain of Ala150 (in the β2-strand) and the side-
chains of Lys138 and Asp139 (in the α-helix 1), respectively (Fig.
2D). In addition, the Arg117 side-chain in the inter-RRM linker
contacts the N7s of both guanines. Finally, A7’s N6 amino group
is hydrogen-bonded with Asp136 from α-helix 1, and its H2
interacts with the His183 side-chain (in the α2–β4 loop) (Fig.
2D). No speciﬁc contact is observed for A1, U2, G3, A4, and C8.
Overall, the structure revealed that the SRSF1 pseudo-RRM
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Fig. 2. Overview of the solution structure of SRSF1 pseudo-RRM in complex with 5′-UGAAGGAC-3′ RNA. (A) Overlay of the 16 lowest-energy structures
superimposed on the backbone of the structured parts of the protein and heavy atoms of RNA. The protein backbone is shown in gray, and heavy atoms
are shown in orange (P atoms), yellow (C atoms for RNA), green (C atoms for protein), red (O atoms), and blue (N atoms). Only the ordered regions of
the RRM (residues 116–193) and RNA (A4 to C8) are shown. (B) The structure of the complex is shown in ribbon (protein backbone) and stick (RNA)
representation. The color scheme is the same as in A. Important protein side-chains involved in RNA interactions are represented as sticks. (C ) Stereo
view of the structure of the SRSF1 pseudo-RRM in complex with RNA. (D and E ) Two views of the molecular recognition of the 5′-GGA-3′ RNA sequence
by the pseudo-RRM. Protein–RNA interactions involving G5, G6, and A7 nucleotides are shown. Color schemes are as in A. Hydrogen bonds are represented
by purple dashed lines.
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recognizes a 5′-GGA-3′ motif, with a majority of the contacts to
the RNA involving the highly conserved S133WQDLKD139 se-
quence within α-helix 1.
In good agreement with the structure, the domain binds 5′-
UGAAGGAC-3′ and 5′-AGGAC-3′ RNAs with almost the same
afﬁnity (Kd of 0.8 and 1 μM, respectively) (Fig. 1 and SI Ap-
pendix, Fig. S3). Moreover, substitutions of either G5 or G6 by
adenines led to no detectable binding measured by ITC, and
substitution of A7 by a guanine or a cytosine decreased the af-
ﬁnity by a factor of two or three, respectively (SI Appendix, Fig.
S3). The invariant SWQDLKD motif located in α-helix 1 of
pseudo-RRMs represents a sequence signature of these domains
(43). Our structure clearly explains this conservation, considering
that, except for the leucine that anchors α-helix 1 into the do-
main hydrophobic core, each residue of this heptapeptide con-
tacts the RNA (Fig. 2). We measured a ﬁve- to 10-fold decrease
in the RNA-binding afﬁnity when we mutated each of these
residues individually (SI Appendix, Fig. S4).
Isolated SRSF1 Pseudo-RRM Regulates Splicing Events in Cells. We
next investigated whether the RNA-binding speciﬁcity we de-
termined for SRSF1 pseudo-RRM is relevant in vivo in the
context of the full-length protein. We transfected human cells
with several variants of SRSF1 and analyzed their effect on the
splicing of insulin-like growth factor 1 (IGF1) exon 5, which has
an SRSF1-dependent purine-rich ESE containing a GGA motif
(Fig. 3A) (48). As previously reported (48), exon 5 inclusion
increased in the presence of the SRSF1 WT protein (Fig. 3 B–E).
Each single amino acid substitution introduced into the full-
length protein and expected to affect the binding of SRSF1
pseudo-RRM to RNA severely reduced the splicing enhance-
ment of IGF1 exon 5 (Fig. 3 B–E, lanes 8–13 and 15). Such large
changes in splicing were surprising, considering that the muta-
tions tested decreased RNA-binding afﬁnity only by ﬁve- to 10-
fold (SI Appendix, Fig. S4). This effect might originate from the
overexpression of these protein variants resulting in nuclear
concentrations close to their Kd. Conversely, mutation of Tyr149,
which is not involved in the interaction with RNA, did not have
a signiﬁcant effect on splicing (Fig. 3 B–E, lane 14). These results
indicate that, in the context of the full-length protein, SRSF1
pseudo-RRM uses the mode of RNA interaction shown in our
structure. In good agreement with the dominant function of the
pseudo-RRM in the recognition of purine-rich ESEs by SRSF1,
deletion of the pseudo-RRM (ΔRRM2) prevented this splicing
enhancement, whereas deletion of the canonical RRM1 or the
RS domain still allowed exon 5 inclusion, although less efﬁciently
than in the full-length protein (Fig. 3 B–E, lanes 1–5). However,
the increase in the percentage of exon 6 inclusion observed in the
absence of the RS domain shows that this part of the protein also
is involved in the regulation of IGF1 alternative splicing (Fig. 3E,
lane 5). More surprisingly, unlike RRM1, the isolated RRM2
could enhance exon 5 splicing to nearly the same extent as SRSF1
after deletion of the RS domain (ΔRS) and more than RRM1-
deleted SRSF1 (ΔRRM1) (Fig. 3 B–E, lanes 1–7), showing that
the pseudo-RRM can activate splicing as a single domain in vivo.
In contrast to the effect observed with IGF1 exon 5, SRSF1
promotes FAS/CD95 exon 6 skipping, which gives rise to an
antiapoptotic isoform (Fig. 4A) (49). To understand better the
mode of action of SRSF1 pseudo-RRM in splicing, we in-
vestigated its role in splicing of FAS exon 6. As shown in Fig. 4,
the isolated pseudo-RRM also could repress splicing of FAS
exon 6, even more efﬁciently than the full-length protein (Fig. 4
B–D). Together with our data for IGF1, these results demon-
strate that the isolated pseudo-RRM can recapitulate the effects
of full-length SRSF1 either as an activator or as a repressor of
exon inclusion, depending on the pre-mRNA substrate. Similar
to our observations for IGF1 exon 5, mutating Lys138 or Asp139
in the SWQDLKD motif of the domain impaired the ability of
the isolated RRM to promote FAS exon 6 skipping (Fig. 4 B–D).
These data indicate that binding of the SRSF1 pseudo-RRM to
RNA via α-helix 1 is required for its function as a regulator of
alternative splicing.
To determine whether the pseudo-RRM can regulate splic-
ing of additional SRSF1 target genes, we analyzed the splicing
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Fig. 3. Effect of SRSF1 mutations on IGF1 exon 5 splicing in cells. (A)
Schematic representation of the IGF1minigene used for the cotransfection
experiments, with the location of primers (arrows) used to amplify the
mRNA isoforms containing either exon 5 or exon 6. Thicker boxes, thinner
boxes, and lines represent exons, UTRs, and introns, respectively. (B) Western
blots showing the relative expression levels of the different T7-tagged
versions of SRSF1, with β-catenin levels used as a reference. (C ) RT-PCR
gels showing the levels of exon 5 and exon 6 mRNA isoforms upon over-
expression of either WT SRSF1 or various mutant versions in HeLa cells.
GAPDH was used as a reference for loading. (D and E ) Graphs showing
the relative band intensities of the exon 5 (D) or exon 6 (E ) mRNA iso-
forms upon overexpression of various SRSF1 versions. n = 4; error bars
indicate SD.
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patterns of 18 endogenous SRSF1 targets. Among these, MKNK2
and MSTR1/RON were shown previously to be regulated by
SRSF1, whereas the remaining splicing events correspond to
targets identiﬁed by RNA-seq in HeLa cells. We performed
semiquantitative radioactive RT-PCR on RNA from HeLa cells
upon two- to threefold overexpression of either full-length
SRSF1 or the pseudo-RRM only (Fig. 5A). To enrich for cells
expressing SRSF1 or the pseudo-RRM, we cotransfected GFP
to enable sorting of the cells by ﬂow cytometry. We observed that
seven of the 18 splicing events responded to expression of the
pseudo-RRM or the full-length protein to a similar extent (Fig.
5 B–D and SI Appendix, Fig. S5). Moreover, the pseudo-RRM
promoted exon skipping or exon inclusion, depending on the
particular SRSF1 splicing target. These results suggest that SRSF1
pseudo-RRM is sufﬁcient for the regulation of a substantial
fraction of SRSF1 splicing targets.
SRSF1 Pseudo-RRM Competes Against hnRNP A1. We then tried to
determine how the isolated SRSF1 pseudo-RRM regulates al-
ternative splicing. Because of the relatively small size of the
domain, it is unlikely that it would act on splicing by recruiting
spliceosome components. Indeed, it was reported recently that
both RRMs of SRSF1 are required to interact with U1-70K (32).
A more tempting hypothesis could be that the pseudo-RRM
regulates splicing by competing for RNA binding with one or
several splicing factors. Previous studies indicated that hnRNP
A1 is an efﬁcient competitor of SRSF1 full-length protein (50,
51). HnRNP A1 recognizes AGG motifs sequence speciﬁcally
(52). Because we showed that SRSF1 pseudo-RRM recognizes
GGA, a sequence containing AGGA in principle could be rec-
ognized by both proteins. To test our hypothesis, we performed
in vivo competition assays using IGF1 and FAS minigenes with
AGGA elements (Fig. 6). Increasing the expression of hnRNP
A1 promoted IGF1 exon 5 skipping (Fig. 6A, Upper, lanes 1–4)
and, more surprisingly, FAS exon 6 inclusion (Fig. 6B, Upper,
lanes 1–4), thus exhibiting an effect on FAS and IGF1 splicing
opposite of that of SRSF1 (Fig. 6 A and B, Lower, lanes 1–4). In
addition, the effects of hnRNP A1 on FAS and IGF1 splicing
were efﬁciently reversed by overexpression of the SRSF1
pseudo-RRM alone (Fig. 6 A and B, Lower, lanes 5–8). Similarly,
increasing the expression of hnRNP A1 prevented SRSF1
RRM2 from promoting IGF1 exon 5 inclusion and FAS exon 6
skipping (Fig. 6 A and B, Upper, lanes 5–8). These results suggest
that the isolated SRSF1 pseudo-RRM can stimulate exon in-
clusion or exon skipping (depending on the substrate) by com-
peting with hnRNP A1.
Unusual Mode of Interaction of Pseudo-RRMs with RNA Is Conserved.
With the exception of R117 and H183, all of the residues of
SRSF1 pseudo-RRM involved in sequence-speciﬁc recognition
of GGA are fully conserved in the pseudo-RRMs of all known
SR proteins containing two RRMs, including Drosophila B52 and
yeast Npl3p (SI Appendix, Fig. S6). This conservation strongly
suggests that all these domains have the same sequence speci-
ﬁcity. To test this hypothesis, we performed afﬁnity measure-
ments by ITC and NMR titrations of various pseudo-RRMs in
complex with 5′-AGGAC-3′ or 5′-UGAAGGAC-3′ RNA (SI
Appendix, Figs. S7 and S8). Although all tested pseudo-RRMs
interacted with these RNAs, their afﬁnity was 2–15 times less
than that of SRSF1 pseudo-RRM. The lower binding afﬁnity of
the pseudo-RRMs of SRSF4, -5, and -6 and Npl3p may result
from the lack of conservation of Arg117 and His183 and/or from
a different amino acid environment around the binding site (Fig.
2 and SI Appendix, Fig. S6). However, the NMR titration with
the 5′-AGGAC-3′ RNA unambiguously showed that α-helix 1
remains the RNA-binding surface for all these pseudo-RRMs, as
evidenced by the large chemical shift changes observed for the
NMR signals corresponding to the tryptophan and glutamine
residues in the conserved SWQDLKD motif and the alanine
located in the β2-strand of these domains (Fig. 7A and SI Ap-
pendix, Fig. S8). In addition, none of the pseudo-RRMs that we
tested interacted with the mutant 5′-AGAAC-3′ RNA, in which
the central G6 was mutated to an adenine (underlined), sup-
porting our observation above that the interaction is sequence
speciﬁc (SI Appendix, Fig. S9). Taken together, these results in-
dicate that this unusual mode of binding and the GGA sequence
speciﬁcity can be generalized to all known pseudo-RRMs. In
agreement with this conclusion, and similar to our observa-
tions with the corresponding full-length proteins, SRSF9’s pseudo-
RRM also activated FAS exon 6 skipping, whereas SRSF5’s
A
5 6 7
pro-apoptotic
anti-apoptotic
B
Fas / CD95 minigene
DC
SRSF1 FL
SRSF1 RRM2
pC
GT
SR
SF
1
WT K1
38
A
D1
39
A
RRM2
pC
GT
SR
SF
1
WT K1
38
A
D1
39
A
5 6 7
5 7
RRM2
pC
GT
SR
SF
1
WT K1
38
A
D1
39
A
R
el
at
iv
e 
Ex
on
 6
 in
cl
us
io
n 
(%
) 80
60
40
20
0
RRM2
Fig. 4. Effect of SRSF1 mutations on FAS exon 6 splicing in cells. (A) Schematic representation of FAS exon 6 minigene. Exon 6 inclusion or skipping generates
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pseudo-RRM was less active (Fig. 7B). These results are con-
sistent with the afﬁnity measurements, considering that the afﬁnity
of SRSF5 for 5′-AGGAC-3′ is ﬁve- to 10-fold lower than that of
the other two pseudo-RRMs (SI Appendix, Fig. S7).
Discussion
Interaction of Pseudo-RRM with RNA, a Conserved Mode of Binding.
In this paper, we show that the pseudo-RRM is primarily re-
sponsible for the interaction of SRSF1 with purine-rich sequences,
which are found in the ESEs targeted by SR proteins in vivo (18).
In addition, our data reveal that all pseudo-RRMs we tested in-
teract speciﬁcally with the 5′-GGA-3′ motif using the same mode
of binding. In particular, the presence of two consecutive guanines
is crucial, because their substitution abolished the interaction
of the pseudo-RRM with RNA (SI Appendix, Figs. S3 and S9).
Consistent with our results, all the consensus sequences obtained
by SELEX for pseudo-RRM-containing SR proteins comprise at
least one GG dinucleotide (18), and RNA sequences with the
highest afﬁnity for Npl3p also comprise this motif (53). This very
similar RNA sequence speciﬁcity shared by all pseudo-RRMs
could explain the functional redundancy observed in some cases
for SR proteins (18). However, although the pseudo-RRM plays
a crucial role in RNA recognition and alternative splicing regu-
lation, it is likely that in some cases the speciﬁcity of SR proteins
is modulated by the canonical RRM1 to accommodate longer or
slightly different sequences.
α-Helix 1 of Pseudo-RRMs, a Binding Platform for Both Protein and RNA.
Although previous studies suggested the potential involvement
of the α-helix 1 of SRSF1 pseudo-RRM in protein (42, 54) and
RNA (40, 47) interactions, there was no rational as to how
such a small surface could accommodate both types of poly-
mers. These observations now can be explained by our struc-
ture and by the structure of SRPK1 (54) bound to the SRSF1
pseudo-RRM. To our surprise, we found that the mode of binding
of the α-helix 1 is very similar for both the RNA and the pro-
tein. Remarkably, the side-chains of SRPK1, Trp88, and His90
occupy the same sites as the bases of G6 and G5, respectively.
The backbones of both polymers follow the same path in both
structures with the Gln135 side-chain being hydrogen bonded
with the main-chain of both ligands (Fig. 7C). Note that the
directionality of the polymers is different. In addition, three
nucleotides are needed to replace two amino acids (Figs. 2D
and 7C). This double involvement of α-helix 1 also implies that
SRSF1 phosphorylation by SRPK1 and RNA binding must
be mutually exclusive events. This information is important to
understand better the mode of action of SRSF1 in cells, be-
cause the use of the same binding platform to interact with
either RNA or protein partners most likely dictates sequential
ligand recognition at different regulatory steps in the gene-
expression pathway.
An Additional Mode of RNA Recognition for the Family of RRMs.
Although three subclasses of RRMs were identiﬁed in Eukarya
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Fig. 5. Effect of SRSF1 pseudo-RRM expression on alternative splicing of endogenous SRSF1 target genes. (A) SRSF1 levels in control (pCGT) and in SRSF1- and
RRM2-overexpressing HeLa cells were assessed by radioactive RT-PCR, followed by native PAGE and autoradiography. SRSF1 levels were normalized to ACTB
mRNA and expressed as the fold change compared with control cells (n = 3). ACTB mRNA was used as a loading control. Error bars indicate SEM. (B) Splicing of
known SRSF1 target genes (MKNK2, RON) was analyzed upon SRSF1 and RRM2 overexpression in cells from A, as described above. Representative gels are
shown in SI Appendix, Fig. S5A. The ratio of each splicing isoform was quantiﬁed, and the relative level of exon inclusion was plotted (n = 3; t test ***P <
0.0005, **P < 0.005). Error bars indicate SD. (C and D) RT-PCR analysis of SRSF1 target genes expressed in cells from A that respond to both RRM2 and full-
length SRSF1 (C) or only to full-length SRSF1 (D). Primers located in the exons ﬂanking the alternatively spliced exon (SI Appendix, Table S1) allow ampli-
ﬁcation of either the full-length isoform or the skipped-exon isoform. For representative gels see SI Appendix, Fig. S5 B and C. The ratio of each isoform was
quantiﬁed, and the relative level of exon inclusion was plotted (n ≥ 3; t test ***P < 0.0005, **P < 0.005, *P < 0.01). Error bars indicate SD.
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(44), until now, structural studies have been conducted for only
two of them. Although the canonical RRM binds RNA through
its β-sheet surface (SI Appendix, Fig. S10) (52), the quasi-
RRM uses a totally different recognition interface, involving
the loop regions (SI Appendix, Fig. S10) (55). Our study reveals
the structure of a member of the third subclass, the pseudo-
RRM, bound to RNA and demonstrates the use of another
RNA-binding surface of RRMs, which is centered on α-helix 1
(SI Appendix, Fig. S10). It illustrates the unusual RNA-binding
variability and plasticity of this simple protein module. To date,
only one structure of a bacterial RRM has been shown to in-
teract with RNA using the α-helix 1 (56). However, this RRM is
not a pseudo-RRM, because it lacks a SWQDLKD motif, and
no sequence-speciﬁc contacts were observed with the α-helix 1
(SI Appendix, Fig. S11).
Pseudo-RRM, a Key Domain of SRSF1 for Splicing Regulation. SR
proteins are well known for promoting splice-site selection via
their interaction with ESEs. However, their mode of action
appears to be more diverse than anticipated, with a variety of
possible mechanisms inﬂuencing splice-site selection. Recent
genome-wide analysis performed in mammalian cells conﬁrmed
the idea that SR proteins can either promote or inhibit exon
inclusion depending on their position on pre-mRNAs (57). Their
binding to intronic sequences was reported primarily to promote
exon skipping (58), but the effect of their interaction with exonic
sequences seems to be more complex. It was proposed that the
binding of SR proteins to alternative exons promotes their in-
clusion, whereas their interaction with a ﬂanking exon causes
skipping of the internal alternative exon (22, 59).
Here, we found that the isolated pseudo-RRM of SRSF1 is
sufﬁcient to modulate splicing of nearly half of the tested SRSF1
target genes (Fig. 5 and SI Appendix, Fig. S5). We propose that
the domain either activates or inhibits splicing by competing
with binding of the splicing repressor hnRNP A1 (50, 51) to a
5′-AGGA-3′ motif, which contains overlapping binding sites
for both proteins (5′-AGG-3′ and 5′-GGA-3′ for hnRNP A1 and
SRSF1 pseudo-RRM, respectively) (SI Appendix, Fig. S10). In the
context of IGF1, the motif is located in alternative exon 5, and
the pseudo-RRM activates inclusion of the targeted exon,
whereas hnRNP A1 represses splicing (Figs. 6A and 8A). An
opposite effect was observed with FAS, because SRSF1 pseudo-
RRM promotes exon 6 skipping, and hnRNP A1 activates its
inclusion (Fig. 6B). The effect observed with hnRNP A1 was
surprising, because hnRNPs were shown primarily to mediate
splicing repression from exonic positions (60–62). Nevertheless,
a study performed in parallel with our work recently reported the
same effect of hnRNP A1 on FAS exon 6 splicing (63). The
authors identiﬁed the binding site of this splicing factor on exon
5, close to the 5′ splice site. Remarkably, the binding sequence
comprises a 5′-AGGA-3′ motif, which could explain the com-
petition we observed between SRSF1 pseudo-RRM and hnRNP
A1 on FAS alternative splicing (Fig. 8B). In addition, the 3′ splice
site of FAS intron 5 also contains a 5′-AGGA-3′ sequence, and
therefore SRSF1 binding could block recognition of this 3′ splice
site by U2AF35, thus contributing to exon 6 skipping (Fig. 8B).
In this context, the function of hnRNP A1 in 3′ splice-site
proofreading and 3′ splice-site recognition (64) also could help
explain the antagonism between SRSF1 and hnRNP A1 in the
regulation of FAS alternative splicing. Finally, our data conﬁrm
that the effect of SR and hnRNP proteins on splicing is position
dependent (65).
Interestingly, our data obtained with the SRSF1 pseudo-RRM
alone ﬁt perfectly with the above-mentioned mode of action of
SR proteins in splicing regulation (22). Indeed, the binding of
SRSF1 pseudo-RRM to the alternative exon of IGF1 itself
activates its inclusion (Fig. 8A), whereas interaction of the do-
main with the ﬂanking exon 5 and/or with the 3′ splice site of
intron 5 promotes skipping of FAS alternative exon 6 (Fig. 8B).
We still need to understand the link between SRSF1 pseudo-
RRM and the spliceosome machinery, but our data indicate that
this domain can be crucial and even sufﬁcient to regulate these
types of splicing events. Finally, the activity of pseudo-RRMs in
splicing is likely to be inﬂuenced by multiple additional parame-
ters, including formation of RNA secondary structures or com-
petition with other proteins targeting overlapping binding sites
(57, 58), which may limit the accessibility to these domains of
5′-AGGA-3′ motifs that are not involved in splicing regulation.
Taken together, our results suggest that the pseudo-RRM can
activate or repress splicing, depending on the position of the
sequence bound by SRSF1 and hnRNP A1 (an AGGA motif
located in an ESE or close to a splice site, respectively) (Fig. 8).
Remarkably, and contrary to the usually invoked mechanism of
action, in this competitive model, the RS domain of the SR pro-
teins is dispensable. Finally, our detailed insights into the unusual
mode of RNA binding and mode of action of SR proteins should
help facilitate the design of molecules that can shift the balance
of alternative splicing isoforms for therapeutic purposes.
Accession Codes. We deposited the chemical shifts of SRSF1
RRM2–UGAAGGAC in the BioMagResBank under accession
number 19248. We have deposited the coordinates of the SRSF1
RRM2–UGAAGGAC structures in the Protein Data Bank (PDB)
under the PDB ID 2M8D.
Materials and Methods
Preparation of RNA–Protein Complexes. We cloned in the pET28 expression
vector all pseudo-RRM ORFs corresponding to amino acids 107–203 of SRSF1,
103–193 of B52, 193–282 of Npl3p, 97–178 of SRSF4, 101–183 of SRSF5, 103–
189 of SRSF6, and 103–185 of SRSF9, as well as SRSF1 RRM1 (residues 1–97)
and SRSF1 RRM1+2 (residues 1–203). These recombinant proteins were fused
to an N-terminal 6×His tag and were overexpressed at 37 °C in Escherichia
coli BL21 (DE3) codon plus cells in minimal M9 medium containing 1 g/L
15NH4Cl and 4 g/L glucose (for
15N-labeled protein) or 1 g/L 15NH4Cl and 2 g/L
13C-glucose (for 15N- and 13C-labeled protein). A GB1 tag was fused at the
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Fig. 6. Effect on IGF1 and FAS splicing of SRSF1 pseudo-RRM and hnRNP A1
coexpression in cells. (A) RT-PCR gels showing the levels of IGF1 exon 5 and
exon 6 mRNA isoforms upon coexpression of hnRNP A1 and SRSF1 pseudo-
RRM in HeLa cells. (Upper) The SRSF1 pseudo-RRM was coexpressed with
increasing amounts of hnRNP A1. (Lower) hnRNP A1 was coexpressed with
increasing amounts of the SRSF1 pseudo-RRM. GAPDH was used as a refer-
ence for loading. The black arrow indicates the junction between two ini-
tially distant lanes present in the same gel. (B) As in A, RT-PCR gels show the
levels of FAS exon 6 mRNA isoforms upon coexpression of hnRNP A1 and the
SRSF1 pseudo-RRM.
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N-terminal extremity of the SRSF1 pseudo-RRM to increase the solubility and
stability of the protein. As seen in Fig. 1 and SI Appendix, Fig. S8, we ob-
served the same chemical shift perturbations upon RNA binding in the
presence or absence of the GB1 tag, demonstrating that the tag does not
inﬂuence the pseudo-RRM interaction with RNA.
Proteins were puriﬁed by two successive nickel afﬁnity chromatography
(Qiagen) steps, as previously described (66), dialyzed against NMR buffer
(50 mM L-Glu, 50 mM L-Arg, 0.05% β-mercaptoethanol, and 20 mM NaH2PO4
at pH 5.5) and concentrated to 0.8 mM with a 10-kDa molecular mass cutoff
Centricon device (Vivascience). The SRSF1 RRM1, RRM2, and RRM1+2 pro-
teins used in SI Appendix, Fig. S1 were dialyzed against a buffer that allows
solubility of the protein containing two RRMs at a concentration of 0.2 mM
(150 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 50 mM L-Glu, 50 mM L-Arg,
0.05% β-mercaptoethanol, and 20 mM Na2HPO4 at pH 7).
WT and mutant RNA oligonucleotides were purchased from Dharmacon,
deprotected according to the manufacturer’s instructions, desalted using a
G-15–size exclusion column (Amersham), lyophilized, and resuspended in
NMR buffer.
RNA-protein complexes used to solve structures were formed in NMR
buffer at an RNA:protein ratio of 1:1, at a 0.8 mM concentration.
NMR Measurement All NMR measurements were performed in NMR buffer at
313 K using Bruker AVIII-500 MHz and 700 MHz equipped with a cryoprobe
and AVIII-600MHz and Avance-900MHz spectrometers. Data were processed
using Topspin 2.0 (Bruker) and analyzed with Sparky (www.cgl.ucsf.edu/
home/sparky/).
Protein sequence-speciﬁc backbone and side-chain assignments were
achieved using 2D 1H-15N HSQC, 2D 1H-13C HSQC, 3D HNCA, 3D HNCO, 3D
CBCACONH, 3D HcCH total correlation spectroscopy (TOCSY), 3D nuclear
Overhauser effect spectroscopy (NOESY), 1H-15N HSQC, and 3D NOESY 1H-13C
HSQC aliphatic (for review, see ref. 67). Aromatic proton assignments were
performed using 2D 1H-1H TOCSY and 3D NOESY 1H-13C HSQC aromatic.
Resonance assignments of RNA in complex with SRSF1 pseudo-RRM were
performed using 2D 1H-1H TOCSY, 2D 1H-1H NOESY, 2D 13C 1F-ﬁltered 2F-
ﬁltered NOESY (68), and natural abundance 2D (13C-1H) HSQC in 100% D2O.
Intermolecular NOEs were obtained using 2D 1H-1H NOESY and 3D 13C 1F-
edited 3F-ﬁltered HSQC-NOESY (69) using unlabeled RNA and 15N-labeled
and 15N- and 13C-labeled proteins, respectively. Intermolecular NOEs between
imino protons of the RNA G5 and G6 nucleotides and SRSF1 protons were
obtained using 2D 1H-1H NOESY at 298 K in H2O.
All NOESY spectra were recorded with a mixing time of 150 ms, the 3D
TOCSY spectrumwith amixing time of 23ms, and the 2D TOCSYwith amixing
time of 50 ms.
Structure Calculation and Reﬁnement. AtnosCandid software (70, 71) was
used to generate preliminary structures and a list of automatically assigned
NOE distance constraints for SRSF1 pseudo-RRM in complex with RNA. Peak
picking and NOE assignments were performed using 3D NOESY (15N- and
13C-edited) spectra. Additionally, intraprotein hydrogen-bond constraints
were added based on hydrogen–deuterium exchange experiments on the
amide protons. For these hydrogen bonds, the oxygen acceptors were
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Fig. 7. Pseudo-RRMs use a conserved mode of interaction with RNA, centered on α-helix 1. (A) Selection of chemical-shift perturbations observed for all the
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Structures of the SRSF1 pseudo-RRM bound to the GG dinucleotide of the 5′-UGAAGGAC-3′ RNA and to the Trp-Gly-His tripeptide of SRPK1 are shown. The
side-chains of Trp88 and His90 occupy the same sites as G6 and G5, respectively. The protein backbone is shown in gray, with the side-chains of SRSF1 and
SRPK1 in green and black, respectively. Heavy atoms of RNA are in orange (P atoms), yellow (C atoms), red (O atoms), and blue (N atoms).
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identiﬁed based on preliminary structures calculated without hydrogen-
bond constraints.
Seven iterations were performed, and 100 independent structures were
calculated at each iteration step. Structures of the protein–RNA complexes
were calculated with CYANA (71) by adding the manually assigned intra-
molecular RNA and RNA–protein intermolecular distance restraints. In ad-
dition, hydrogen-bond constraints between protein and RNA were used
based on characteristic chemical-shift perturbations observed upon RNA
binding for amide and carbonyl of the Ala150 backbone (using 2D 1H-15N
HSQC and 3D HNCO spectra, respectively) and of carboxyl groups of the
Asp136 and Asp139 side-chains (using the 3D HNCACO spectrum). Oxygen
acceptors were identiﬁed as described above. For each CYANA run, 50 in-
dependent structures were calculated. These 50 structures were reﬁned with
the SANDER module of AMBER 9.0 (72) by simulated annealing run in im-
plicit water using the ff99 force-ﬁeld (73).
The best structures based on energy and NOE violations were analyzed
with PROCHECK (74). The Ramachandran plot of the SRSF1 pseudo-RRM in
complex with RNA indicates that 72.7% of the residues are in the most fa-
vored regions, 22.5% in the additional allowed regions, 3.8% in the gen-
erously allowed regions, and 1% in the disallowed regions. All of the ﬁgures
showing structures were generated with MOLMOL (75).
ITC. ITC experiments were performed on a VP-ITC instrument (Microcal),
calibrated according to the manufacturer’s instructions. Protein and RNA
samples were dialyzed against the NMR buffer. Concentrations of proteins
and RNAs were determined using optical-density absorbance at 280 and 260 nm,
respectively. Then 20 μM of all of the tested RNAs were titrated with 400 μM
of recombinant protein by 40 injections of 6 μL every 5 min at 40 °C. Raw
data were integrated, normalized for the molar concentration, and analyzed
using Origin 7.0 software according to a 1:1 RNA:protein ratio binding model.
Cell Culture and Transfections. We cultured HeLa cells in DMEM (Invitrogen)
supplemented with 10% (vol/vol) FBS (Invitrogen). We used Fugene 6
transfection reagent (Invitrogen) to cotransfect 2.1 μg of pEGFP-IGF1 mini-
gene (48) with 0.7 μg of pCG-T7::SRSF1 or its mutants, in 40–50% conﬂuent
HeLa cells grown on six-well plates, according to the manufacturer’s rec-
ommendations. For in vivo splicing assays performed with the FASminigene,
cells were cotransfected with 200 ng of FAS minigene plasmid and 1.5 μg of
SRSF1 cDNA expression vectors (full-length or RRM2 derivatives). For the
titration in Fig. 6A the following plasmid amounts were used: Upper, SRSF1
RRM2: 1 μg; hnRNP A1: 1, 2, and 4 μg; Lower, hnRNP A1: 1 μg; SRSF1 RRM2:
1, 2, and 4 μg. In Fig. 6B, Upper, SRSF1 RRM2: 2 μg; hnRNP A1: 0.5, 1, and 2 μg;
Lower, hnRNP A1: 1 μg; SRSF1 RRM2: 1, 2, and 4 μg.
For splicing of endogenous SRSF1 targets, HeLa cells were transfected
using FuGENE 6 (Promega) with 10 μg of pCG-T7-control, -SRFS1 or -RRM2
plasmids (76) together with 1 μg of pEGFP per 10-cm plate. Cells were
trypsinized 48 h after transfection, and GFP-positive cells were sorted on
a Becton Dickinson FACSAria IIU Cell Sorter.
In Vivo Splicing Assays.After 48 h, total RNAwas isolated using TRIzol reagent
(Invitrogen) and treated with DNase I (Promega). Reverse transcription
was performed using ImProm-II reverse transcriptase (Promega) and oligo
dT primers.
For assays performed with the IGF1 minigene, we used the cDNA tem-
plates to perform radioactive PCRs using vector-speciﬁc (pEGFP) primers, as
described (77). For assays involving the FASminigene, we performed RT-PCRs
as described (78). To calculate the IGF1 exon 5 or exon 6 inclusion levels, the
α-32P-dCTP–labeled PCR-amplicons were separated by native PAGE, followed
by phosphorimage analysis on a Fujiﬁlm FLA-5100 instrument (Fuji Medical
Systems USA, Inc.). We quantiﬁed the band intensities using MultiGauge
software version 2.3 (Fujiﬁlm) and normalized the values for the G+C
content according to the DNA sequence. We further normalized the G+C
corrected band intensities of individual isoforms in each lane to the corre-
sponding intensities of GAPDH bands, as a control for loading. We then set
the levels of exon 5 and exon 6 expression from the empty vector lane as 100
and represented the expression levels of these isoforms upon overexpression
of WT-SRSF1 or its mutant forms as fold changes.
For splicing of endogenous SRSF1 targets, radioactive touchdown PCRwith
α-32P-dCTP was used to amplify endogenous transcripts with primers de-
scribed in SI Appendix Table S2. PCR products were separated by 8% native
PAGE, and bands were quantiﬁed with a phosphorimager (Fuji Image
Reader FLA-5100). The signal intensity was normalized ﬁrst to the GC con-
tent of the ampliﬁed transcript and then to the sum of different isoform
mRNAs or to β-actin if only one band was detected. The changes were
expressed as percentages of exon inclusion, using empty vector as a control.
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